Shares of R1 RCM Inc (NASDAQ:RCM) have received a consensus rating of “Hold” from the seven ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $14.25.

Several research firms have commented on RCM. Zacks Investment Research lowered shares of R1 RCM from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 27th. BidaskClub lowered shares of R1 RCM from a “buy” rating to a “hold” rating in a report on Tuesday, January 7th. ValuEngine raised shares of R1 RCM from a “sell” rating to a “hold” rating in a report on Friday, November 1st. KeyCorp lifted their price target on shares of R1 RCM from $14.00 to $15.00 and gave the company an “overweight” rating in a report on Tuesday, January 14th. Finally, Dougherty & Co began coverage on shares of R1 RCM in a report on Friday, January 10th. They set a “buy” rating and a $15.00 price target on the stock.

Several institutional investors have recently made changes to their positions in RCM. JPMorgan Chase & Co. grew its holdings in shares of R1 RCM by 149.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 294,343 shares of the healthcare provider’s stock valued at $3,582,000 after purchasing an additional 176,271 shares during the last quarter. Bank of Montreal Can grew its holdings in shares of R1 RCM by 179.5% during the 2nd quarter. Bank of Montreal Can now owns 13,308 shares of the healthcare provider’s stock valued at $168,000 after purchasing an additional 8,547 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of R1 RCM by 414.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,116,648 shares of the healthcare provider’s stock valued at $26,627,000 after purchasing an additional 1,705,447 shares during the last quarter. Northern Trust Corp grew its holdings in shares of R1 RCM by 0.7% during the 2nd quarter. Northern Trust Corp now owns 1,283,606 shares of the healthcare provider’s stock valued at $16,147,000 after purchasing an additional 8,568 shares during the last quarter. Finally, Parametric Portfolio Associates LLC grew its holdings in shares of R1 RCM by 122.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 464,366 shares of the healthcare provider’s stock valued at $5,842,000 after purchasing an additional 256,003 shares during the last quarter. 70.60% of the stock is currently owned by institutional investors.

RCM stock traded down $0.11 during mid-day trading on Friday, hitting $13.42. The stock had a trading volume of 847,810 shares, compared to its average volume of 999,826. The company has a debt-to-equity ratio of 29.28, a current ratio of 0.94 and a quick ratio of 0.94. R1 RCM has a 52 week low of $7.58 and a 52 week high of $13.99. The firm has a fifty day simple moving average of $12.67 and a 200 day simple moving average of $11.76.

R1 RCM (NASDAQ:RCM) last released its earnings results on Tuesday, November 5th. The healthcare provider reported $0.01 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.08). R1 RCM had a negative net margin of 0.13% and a positive return on equity of 100.31%. The firm had revenue of $301.20 million during the quarter, compared to the consensus estimate of $302.85 million. During the same period in the prior year, the business earned ($0.17) earnings per share. R1 RCM’s quarterly revenue was up 20.3% compared to the same quarter last year. On average, analysts anticipate that R1 RCM will post -0.05 earnings per share for the current fiscal year.

About R1 RCM

R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers.

Recommended Story: S&P 500 Index

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.